Private Management Group’s Humacyte HUMA Stock Holding History

Private Management Group’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,500	Closed	-$45.4K	–	204
2023 Q3	$45.4K	Buy	+15,500	New	+$51.3K	﹤0.01%	185

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Private Management Group's HUMA Position: Q4 2023 in Review

Private Management Group sold out of Humacyte (HUMA) in Q4 2023, closing a stake of 15,500 shares — an estimated $45.4K sold.

Private Management Group first reported a position in HUMA in Q3 2023 and held it in 1 quarter. The position peaked at $45.4K in Q3 2023. 88 funds tracked by Wall St. Rank hold HUMA as of Q4 2023.

Private Management Group reported no remaining Humacyte position as of Q4 2023 after selling out during the quarter.
Private Management Group sold 15,500 Humacyte shares in Q4 2023, an estimated $45.4K.
Private Management Group first reported a position in Humacyte in Q3 2023 and held it in 1 quarter.
Private Management Group's Humacyte position peaked at $45.4K in Q3 2023.
88 funds tracked by Wall St. Rank held Humacyte as of Q4 2023.

Based on Private Management Group's 13F filing for Q4 2023, filed 2 Feb 2024.